Jian Cui

12PUBLICATIONS
55CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsPredictive and prognostic markersMedical infection agents (incl. prions)NanomedicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 30, 2026
Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study (CHAMP-MM).

|Sep 07, 2026
Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

|Jun 04, 2026
PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma.

|Jan 10, 2026
Two Decades of Real-World Study in Newly Diagnosed Multiple Myeloma: Evolving Treatment and Outcomes in China with Reference to the United States.

Jingyu Xu, Meng Shu, Hsingwen Chung

|Nov 30, 2025
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.

Jian Cui, Jingwei Wang, Xiaoyun Li

|Oct 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Mariateresa Fulciniti, Yao Yao, Tommaso Perini

Pageof 2

Frequent Collaborators

8 joint publications

Lugui Qiu

7 joint publications

Gang An

6 joint publications

Jingyu Xu

6 joint publications

Yan Xu